ASH 2017 | Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent

Guillermo Garcia-Manero

Decitabine, a DNA methyltransferase (DNMT) inhibitor, which is given to patients with myelodysplastic syndromes (MDS), is classically administered intravenously. Now, ASTX727, an oral combination of decitabine and the cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), is in Phase II clinical trials for the treatment of MDS (NCT02103478). Here, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the study so far compared with traditional decitabine treatment, and highlights the benefits of an oral version of this treatment. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video